Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

Davina Gale,Katrin Heider,Malcolm Perry,Giovanni Marsico,Andrea Ruiz-Valdepeñas,Viona Rundell,Jerome Wulff,Garima Sharma,Karen Howarth,David Gilligan,Susan Harden,Doris Rassl,Robert C. Rintoul,Nitzan Rosenfeld

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

2021

Davina Gale
Katrin Heider
Malcolm Perry
Giovanni Marsico
Andrea Ruiz-Valdepeñas
Viona Rundell
Jerome Wulff
Garima Sharma
Karen Howarth
David Gilligan
Susan Harden
Doris Rassl
Robert C. Rintoul
Nitzan Rosenfeld

8517Background: Liquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence. Conclusive evidence for utility of ctDNA in ...

Keywords:

in patient
Internal medicine
conclusive evidence
Medicine
Circulating tumor DNA
Oncology
Stage (cooking)
Early Relapse
after treatment
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations